Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
  • Cardio Diagnostics has positioned the science of epigenetics at the center of its diagnostic platform.
  • Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment.
  • Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution.

When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself. Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform.

Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  240.25
+7.56 (3.25%)
AAPL  282.58
-1.20 (-0.42%)
AMD  536.87
+15.28 (2.93%)
BAC  58.03
+0.15 (0.27%)
GOOG  350.14
+15.45 (4.62%)
META  564.25
+14.00 (2.54%)
MSFT  367.21
-5.76 (-1.54%)
NVDA  194.64
+2.11 (1.10%)
ORCL  147.62
-0.91 (-0.62%)
TSLA  412.50
+32.79 (8.63%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.